Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for osteoporosis
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Previous bisphosphonate treatment attenuates the bone-forming effect of teriparatide. We compared the effects of 12 months of romosozumab (AMG 785), a sclerostin monoclonal antibody, versus teriparatide on bone mineral density (BMD) in women with postmenopausal osteoporosis transitioning from (...) bisphosphonate therapy.This randomised, phase 3, open-label, active-controlled study was done at 46 sites in North America, Latin America, and Europe. We enrolled women (aged ≥55 to ≤90 years) with postmenopausal osteoporosis who had taken an oral bisphosphonate for at least 3 years before screening and alendronate the year before screening; an areal BMD T score of -2·5 or lower at the total hip, femoral neck, or lumbar spine; and a history of fracture. Patients were randomly assigned (1:1) via
2017LancetControlled trial quality: predicted high
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis To develop recommendations for prevention and treatment of glucocorticoid-induced osteoporosis (GIOP).We conducted a systematic review to synthesize the evidence for the benefits and harms of GIOP prevention and treatment options. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of evidence. We used a group (...) GC users.Because of limited evidence regarding the benefits and harms of interventions in GC users, most recommendations in this guideline are conditional (uncertain balance between benefits and harms). Recommendations include treating only with calcium and vitamin D in adults at low fracture risk, treating with calcium and vitamin D plus an additional osteoporosis medication (oral bisphosphonate preferred) in adults at moderate-to-high fracture risk, continuing calcium plus vitamin D
Nutrition and osteoporosis prevention for the orthopaedic surgeon: A wholefoods approach Osteoporosis is a prevalent and debilitating condition with no signs of subsiding. Rising numbers of people consuming nutrient-poor diets coupled with ageing populations and sedentary lifestyles appear to be the main drivers behind this.While the nutrients calcium and vitamin D have received most attention, there is growing evidence that wholefoods and other micronutrients have roles to play in primary (...) and potentially secondary osteoporosis prevention.Until recently, calcium and vitamin D were regarded as the main nutrients essential to bone health but now there are emerging roles for iron, copper and selenium, among others.Fruit and vegetables are still not being eaten in adequate amounts and yet contain micronutrients and phytochemicals useful for bone remodelling (bone formation and resorption) and are essential for reducing inflammation and oxidative stress.There is emerging evidence that dried fruits
Abaloparatide (Tymlos) Subcutaneous Injection - osteoporosis in postmenopausal women Tymlos Subcutaneous Injection U.S. Department of Health and Human Services Search FDA Submit search Tymlos Subcutaneous Injection DUPIXENT Company: Radius Health, Inc. Application No.: 208743 Approval Date: 04/28/2017 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF
Bindex for people with suspected osteoporosis Binde Bindex for in x for inv vestigating suspected osteoporosis estigating suspected osteoporosis Medtech innovation briefing Published: 31 May 2017 nice.org.uk/guidance/mib106 pathways Summary Summary The technology technology described in this briefing is Bindex, a portable pulse-echo ultrasound device used to help make decisions on the investigation and treatment of osteoporosis. The inno innovativ vative aspects e aspects are that it is pocket (...) sized and can be connected to and used with any laptop or desktop computer's USB socket. Unlike other quantitative ultrasound that measures sound speed and attenuation in the heel, Bindex makes measurements of the tibia applying thresholds of 90% sensitivity and specificity compared with axial dual-energy X-ray absorptiometry (DXA), to help with decisions on further tests and treatment for osteoporosis. The intended place in ther place in therap apy y would be to use Bindex alongside current
Romosozumab for osteoporosis in men Romosozumab for osteoporosis in men | Innovation Observatory toggle menu Menu Search View All Filter by Speciality Filter by Year Filter by Category This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders. > > > Romosozumab (...) for osteoporosis in men Romosozumab for osteoporosis in men May 2017 Romosozumab arose from a genetic discovery that revealed the body’s own natural ability to increase bone strength. It is a treatment which aims to block the activity of the protein sclerostin. This diminishes bone breakdown and removal and stimulates bone formation, thereby increasing bone strength. The effectiveness and safety of romosozumab for the treatment of osteoporosis in men has been studied in a phase III clinical trial. The study
Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update from the American College of Physicians. This guideline updates the 2008 American College of Physicians (ACP) recommendations on treatment of low bone density and osteoporosis to prevent fractures in men and women. This guideline is endorsed by the American Academy of Family Physicians.The ACP Clinical Guidelines Committee based these recommendations on a systematic review (...) and vertebral fractures in women who have known osteoporosis. (Grade: strong recommendation; high-quality evidence).ACP recommends that clinicians treat osteoporotic women with pharmacologic therapy for 5 years. (Grade: weak recommendation; low-quality evidence).ACP recommends that clinicians offer pharmacologic treatment with bisphosphonates to reduce the risk for vertebral fracture in men who have clinically recognized osteoporosis. (Grade: weak recommendation; low-quality evidence).ACP recommends against
Teriparatide (Movymia) - osteoporosis 10 November 2016 EMA/88527/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report Movymia International non-proprietary name: teriparatide Procedure No. EMEA/H/C/004368/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 (...) authorisation to the European Medicines Agency (EMA) for Movymia, through the centralised procedure falling within the Article 3(1) and point 1 of Annex of Regulation (EC) No 726/2004. The applicant applied for the following indication: Movymia is indicated in adults. Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and nonvertebral fractures but not hip fractures has been demonstrated
Systematic guideline search and appraisal, as well as extraction of relevant recommendations, for a DMP "osteoporosis" 1 Translation of Chapters 1 to 6 of the final report Systematische Leitlinienrecherche und -bewertung sowie Extraktion relevanter Empfehlungen für ein DMP Osteoporose (Version 1.0; Status: 1 April 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally (...) binding. Extract Systematic guideline search and appraisal, as well as extraction of relevant recommendations, for a DMP “osteoporosis” 1 IQWiG Reports – V14-03 Extract of final report V14-03 Version 1.0 Guideline search and appraisal for a DMP “osteoporosis” 1 April 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Systematic guideline search and appraisal, as well as extraction of relevant
Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy. Corticosteroid treatment is considered the 'gold standard' for Duchenne muscular dystrophy (DMD); however, it is also known to induce osteoporosis and thus increase the risk of vertebral fragility fractures. Good practice in the care of those with DMD requires prevention of these adverse effects. Treatments to increase bone mineral density include (...) bisphosphonates and vitamin D and calcium supplements, and in adolescents with pubertal delay, testosterone. Bone health management is an important part of lifelong care for patients with DMD.To assess the effects of interventions to prevent or treat osteoporosis in children and adults with DMD taking long-term corticosteroids; to assess the effects of these interventions on the frequency of vertebral fragility fractures and long-bone fractures, and on quality of life; and to assess adverse events.On 12
Diagnosis and treatment of osteoporosis. Diagnosis and treatment of osteoporosis. | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 14 Apr 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group is 100% composed of volunteers and interested (...) * Remember Me Don't have an account? The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018 because federal funding through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our . Guideline Summary NGC:011292 2017 Jul NEATS Assessment Diagnosis and treatment of osteoporosis. Allen S, Forney-Gorman A, Homan M, Kearns A, Kramlinger A, Sauer M. Diagnosis and treatment of osteoporosis. Bloomington
Diagnosis and Treatment of OsteoporosisOsteoporosis, Diagnosis and Treatment of | ICSI The MN Health Collaborative includes physicians and other representatives from major healthcare organizations working together to address major health topics affecting Minnesota communities today. ICSI has been developing evidence-based clinical practice guidelines to improve patient care since 1993. ICSI helps forward-focused Minnesota health organizations find ways to redefine and redesign systems (...) and the market. Together, we aim to improve care and reduce costs for our patients, families and communities. e Guidelines Osteoporosis, Diagnosis and Treatment of REVISION DATE: JULY 2017 / NINTH EDITION GUIDELINE SUMMARY This guideline is targeted toward identification and treatment of adult patients with osteopenia and osteoporosis. This includes a detailed discussion of risk factors for bone loss and primary prevention with all patients presenting for routine health visits. It also addresses
American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis ARTHRITIS & RHEUMATOLOGY Vol. 69, No. 8, August 2017, pp 1521–1537 DOI 10.1002/art.40137 V C 2017, American College of Rheumatology SPECIAL ARTICLE 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis Lenore Buckley, 1 Gordon Guyatt, 2 Howard A. Fink, 3 Michael Cannon, 4 Jennifer Grossman, 5 Karen E. Hansen, 6 Mary (...) . Results. Because of limited evidence regarding the benefits and harms of interventions in GC users, most recommendationsinthisguideline areconditional (uncertain balance between benefits and harms). Rec- ommendations include treating only with calcium and vitamin D in adults at low fracture risk, treating with calcium and vitamin D plus an additional osteoporosis medication(oralbisphosphonatepreferred)inadultsat moderate-to-high fracturerisk,continuing calcium plus
Treatment of Low Bone Density or Osteoporosis Treatment of Low Bone Density or Osteoporosis -- Clinical Recommendation Welcome Search Search Specify your search AAFP.org Patient Care Clinical Practice Guideline Treatment of Low Bone Density or Osteoporosis Treatment of Low Bone Density or Osteoporosis (Endorsed, April 2017) The guideline, Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women , was developed by the American College of Physicians and was endorsed (...) by the American Academy of Family Physicians. Key Recommendations Pharmacologic treatment with alendronate, risedronate, zoledronic acid, or denosumab should be prescribed for women with osteoporosis to reduce the risk of hip and vertebral fractures. Pharmacologic treatment should continue for five years, during which time bone density monitoring should not be done. Menopausal estrogen therapy, menopausal estrogen plus progesterone, or raloxifene should not be used in women with osteoporosis. The decision